Alzheimer's Disease: RO7126209 IV Treatment Study

We are investigating a new intravenous medication for individuals with mild to moderate Alzheimer's disease. The study aims to assess its safety and how it affects the brain over multiple doses.

>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessPartially RemoteInvestigational MedicinesInjectionNeurologyPsychiatry

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Florbetapir (18f)
Florbetapir (18F) is a radioactive tracer used in PET scans to detect abnormal protein deposits in the brain linked to Alzheimer's disease.
Flortaucipir (18f)
Flortaucipir (18F) is a radioactive imaging tracer used in PET scans to visualize tau protein build-up in the brain.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Trontinemab

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Vitamed Galaj I Cichomski Sp. j.
NZOZ Vitamed
Bydgoszcz, Poland
Clinical Research Center Sp. z o.o. Medic-R sp.k.
Clinical Research Center Sp. z o.o. MEDIC-R Spolka Komandytowa
Poznań, Poland
Euromedis Sp. z o.o.
Osrodek Badan Klinicznych Euromedis
Szczecin, Poland
Sponsor: F. Hoffmann-La Roche AG
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.